Saturday 17 October 2026
Export PROK’s income statement to Excel — free account
ProKidney Corp.
PROK Healthcare Biotechnology
ProKidney Corp.’s revenue for fiscal 2025 (year ended December 2025) was $893,000.00, up 1,075.0% from fiscal 2024. In the quarter to June 2026, revenue fell 32.1%, EPS fell 15.4% and free cash flow fell 28.0%, each against the same quarter a year earlier.
1.33
0.13
−8.90%
Follow PROK
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
465.26 | 285.77 | 335.98 | 0.00 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(9.43) | (6.09) | (9.23) | (12.28) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
243.71 | 33.11 | 33.98 | 0.00 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.41) | (0.22) | (0.25) | (0.49) | |
EV/FCF |
(1.41) | (0.22) | (0.26) | (0.38) | |
Quick Ratio |
8.04 | 8.71 | 8.82 | 9.39 | |
Current Ratio |
8.36 | 9.06 | 9.13 | 10.32 | |
Net Debt/EBITDA |
3.89 | 5.20 | 6.20 | 7.37 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.42 | 2.08 | 1.69 | 1.61 | |
Capex/Depreciation |
(2.28) | (2.28) | 6.78 | (3.11) | |
Interest Coverage |
(48,373.00) | (2,995.53) | (45,371.00) | (19,269.50) | |
Research and Development Expense of Revenue |
24,063.33% | 14,974.34% | 15,180.89% | 12,359.91% | |
Selling, General and Administrative Expense of Revenue |
8,285.33% | 5,007.52% | 5,084.00% | 5,500.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
3,729.33% | 2,188.05% | 2,534.67% | 3,076.50% | |
Graham Net Nets |
(2.48) | (4.26) | (3.55) | (3.24) | |
Graham Number |
7.66 | 9.27 | 9.40 | 9.61 | |
Earnings Yield |
(26.96%) | (29.61%) | (23.21%) | (22.73%) | |
Free Cash Flow Yield |
(37.18%) | (51.90%) | (39.03%) | (44.91%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.22) | (0.29) | (0.24) | (0.20) | |
Capex per Share |
(0.02) | (0.03) | 0.09 | (0.04) | |
Free Cash Flow per Share |
(0.24) | (0.32) | (0.15) | (0.24) | |
Cash per Share |
0.97 | 1.58 | 2.02 | 2.01 | |
Shareholders Equity per Share |
(4.74) | (7.21) | (7.55) | (7.47) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(4.74) | (7.21) | (7.55) | (7.47) | |
Free Cash Flow |
(44.21) | (45.47) | (20.05) | (31.79) | |
Working Capital |
167.06 | 208.97 | 249.94 | 270.93 | |
Capital Expenditures |
(3.83) | (3.78) | 12.46 | (5.20) | |
Net Current Asset Value |
(942.78) | (1,081.66) | (1,066.09) | (1,059.64) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
25.55 | 16.75 | (55.39) | 23.95 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.37 | 1.39 | 1.79 | 3.17 | |
Average Payables |
2.03 | 2.86 | 2.29 | 2.40 | |
Average Assets |
310.57 | 349.42 | 388.32 | 413.20 | |
Average Common Equity |
(943.02) | (1,011.17) | (1,003.08) | (993.87) |
Columns are period end dates